The FDA has approved sotatercept-csrk, the first activin signaling inhibitor therapy, for the management of patients with pulmonary arterial hypertension (PAH). Based on the Phase 3 STELLAR trial,...
Researchers conducted a systematic review to assess the effect of CPAP treatment for obstructive sleep apnea on secondary cardiovascular disease events.
This COVID-19 roundup includes coverage of the FDA’s guidance for the correct Moderna vaccine dosage for pediatric patients, COVID-19 outcomes for patients with hypertension and diabetes, and the risk of...
This COVID-19 roundup includes coverage on the outcomes associated with two omicron subvariant treatments, FDA’s authorization of Novavax vaccine, the NIH Treatment Guidelines Panel’s recommendation of...
In a placebo-controlled, randomized trial, researchers tested the efficacy of cytisinicline—a smoking cessation medication—for those who would like to quit smoking.
Martha Kingman, FNP-C, DNP, and Bradley A. Maron, MD, review the latest guidelines and best practices for the primary care provider in the diagnosis and management of pulmonary arterial hypertension and...
This COVID-19 roundup includes coverage on the FDA-approved oral antiviral treatment for adults with mild-to-moderate COVID-19, how antidepressant medication may lower the incidence of COVID-19, a study...
Following a multicenter clinical trial, a new treatment for pneumonia caused by Acinetobacter baumannii-calcoaceticus has been approved for use in adults.
The American Thoracic Society released a set of guidelines addressing the use of pulmonary rehabilitation in patients with chronic obstructive pulmonary disorder and other respiratory diseases.
Following three clinical trials, the FDA has approved a new preventive treatment for neonates, infants, and toddlers that prevents respiratory syncytial virus (RSV) in those age populations.
